Literature DB >> 31265878

Fibroblasts in cancer: Defining target structures for therapeutic intervention.

Maximilian Boesch1, Florent Baty2, Holger Rumpold3, Sieghart Sopper4, Dominik Wolf5, Martin H Brutsche2.   

Abstract

The functional importance of the tumor stroma for cancer growth and progression is increasingly recognized, but has not resulted in notable therapeutic developments yet. Within the mesenchymal tumor microenvironment, cancer-associated fibroblasts take the center stage and fuel tumor progression in various ways including malignant cell potentiation, immune regulation and fibrosis. However, recent studies have demonstrated pronounced heterogeneity of the fibroblastic tumor stroma, which comprises a plethora of individual cell subsets with varying phenotypes and functions, some of which suppress malignant growth through immune engagement or crosstalk with the tumor vasculature. This article summarizes the various levels at which the fibroblastic tumor stroma may impact cancer progression and highlights potential target structures for future therapeutic intervention(s).
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Cancer stem cell; Cancer treatment; Cancer-associated fibroblast; Fibroblastic stromal cell; Immunotherapy; Tumor microenvironment

Mesh:

Year:  2019        PMID: 31265878     DOI: 10.1016/j.bbcan.2019.06.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  7 in total

1.  Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.

Authors:  Tongtong Wei; Jinjing Song; Kai Liang; Li Li; Xiaoxiang Mo; Zhiguang Huang; Gang Chen; Naiquan Mao; Jie Yang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

2.  MicroRNA-497-5p Is Downregulated in Hepatocellular Carcinoma and Associated with Tumorigenesis and Poor Prognosis in Patients.

Authors:  Lin-Lin Tian; Bin Qian; Xiao-Hui Jiang; Yu-Shan Liu; Tong Chen; Cheng-You Jia; Ya-Li Zhou; Ji-Bin Liu; Yu-Shui Ma; Da Fu; Sen-Tai Ding
Journal:  Int J Genomics       Date:  2021-03-16       Impact factor: 2.326

3.  Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation.

Authors:  Merry L Lindsey; Kristine Y Deleon-Pennell; Amy D Bradshaw; R Amanda C Larue; Daniel R Anderson; Geoffrey M Thiele; Catalin F Baicu; Jeffrey A Jones; Donald R Menick; Michael R Zile; Francis G Spinale
Journal:  J Card Fail       Date:  2020-05-21       Impact factor: 6.592

4.  Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 Axis.

Authors:  Yu-Shui Ma; Kai-Jian Chu; Chang-Chun Ling; Ting-Miao Wu; Xu-Chao Zhu; Ji-Bin Liu; Fei Yu; Zhi-Zhen Li; Jing-Han Wang; Qing-Xiang Gao; Bin Yi; Hui-Min Wang; Li-Peng Gu; Liu Li; Lin-Lin Tian; Yi Shi; Xiao-Qing Jiang; Da Fu; Xiong-Wen Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-01       Impact factor: 8.886

5.  Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC.

Authors:  Arik Bernard Schulze; Lars Henning Schmidt; Birthe Heitkötter; Sebastian Huss; Michael Mohr; Alessandro Marra; Ludger Hillejan; Dennis Görlich; Peter J Barth; Jan Rehkämper; Georg Evers
Journal:  Thorac Cancer       Date:  2019-11-24       Impact factor: 3.500

6.  Crucial contribution of GPR56/ADGRG1, expressed by breast cancer cells, to bone metastasis formation.

Authors:  So-Ichiro Sasaki; Di Zhang; Sadahiro Iwabuchi; Yamato Tanabe; Shinichi Hashimoto; Akira Yamauchi; Katsuhiro Hayashi; Hiroyuki Tsuchiya; Yoshihiro Hayakawa; Tomohisa Baba; Naofumi Mukaida
Journal:  Cancer Sci       Date:  2021-10-20       Impact factor: 6.716

Review 7.  Tumour neoantigen mimicry by microbial species in cancer immunotherapy.

Authors:  Maximilian Boesch; Florent Baty; Sacha I Rothschild; Michael Tamm; Markus Joerger; Martin Früh; Martin H Brutsche
Journal:  Br J Cancer       Date:  2021-04-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.